Title of Invention	"PHARMACEUTICAL TABLET"
Abstract	A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coaling comprises aellan gum. The tablet is suitable for peroral or inlraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

Title of Invention

"PHARMACEUTICAL TABLET"

Abstract

A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coaling comprises aellan gum. The tablet is suitable for peroral or inlraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

Full Text	PHARMACEUTICAL TABLET FIELD OF THE INVENTION The present invention relates to orally deliverable pharmaceutical dosage forms, more particularly tablets. BACKGROUND OF THE INVENTION Tablets are the most common and convenient pharmaceutical dosage form for oral administration of medications. It is an important functional attribute of a tablet that it be readily identifiable by appearance, including by size, shape, surface texture, markings and color. Such ready identifiability is important in minimizing dispensing errors and in enabling patients on multiple medication to distinguish among the drugs they take at different times or frequencies. A vast array of drugs are now formulated as tablets, many of these drugs being formulated at different dosage strengths, and it is therefore becoming ever more important, yet ever more difficult to insure, that any new tablet has unique appearance. In particular, the range of readily distinguishable colors available to the formulator of tablets is rather limited. To some extent this problem has been alleviated by use of particolored, bicolored or multicolored tablets. However, a need remains in the art for tablets having unique surface color patterns. In the case of coated tablets, color can be an attribute of the surface coating. For example, a range of opaque pigments are available for incorporation in tablet coating compositions such as those based on ethylcellulose; these pigments tend to impart a solid white or colored appearance to a coated tablet. Alternatively, the surface coating can be clear and transparent, and the color of the coated tablet is controlled by the color of the tablet core underlying the coating. U.S. Patent No. 6,326,028 to Nivaggioli et al, incorporated herein by reference, discloses a tablet coating comprising gellan gum. Such a coating is said to be useful for tablets to be taken orally, and to confer benefits in appearance, identification, mouth feel, reduced dust, stability, color and/or swallowability. International Patent Publication No. WO 01/10406, incorporated herein by reference, discloses compositions said to be suitable for a wide range of routes of administration of sildenafil citrate, including buccal and sublignual routes. Preferred compositions disclosed are said to comprise a solution, gel, semisolid, suspension, metered dose device, transdermal patch or film. It is indicated that such compositions can include a gelling system, for example gellan gum 0.5% to 10%. International Patent Publication No. WO 02/05820, incorporated herein by reference, discloses film dosage forms comprising sildenafil citrate. These dosage forms are prepared by mixing a solid dispersion of sildenafil citrate and a water-soluble sugar with a hydrocolloid and optionally other ingredients, and are said, upon placement on a mucosal surface, to form a coating that subsequently disintegrates and dissolves to release sildenafil. Gellan sodium salt is listed among hydrocolloids said to be useful in such film dosage forms. U.S. Patent No. 6,291,506 to Levin, incorporated herein by reference, discloses that the ophthalmic drug carvedilol can be formulated for ocular administration by suspending it in an agent such as gellan gum that will increase corneal contact time with the drug. Other possible delivery modes for the drug are contemplated therein. A claim is included to a method wherein the drug is delivered by a selection of routes including sublingually. SUMMARY OF THE INVENTION There is now provided a pharmaceutical tablet comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum. The tablet is particularly suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, illustratively a human subject. The term "peroral" herein refers to administration via the mouth involving swallowing of the tablet without substantial prior disintegration of the tablet in the mouth, so that absorption of the drug typically occurs in the gastrointestinal tract. The term "intraoral" herein refers to administration by placement of the tablet in the mouth of the subject, where the tablet disintegrates and/or dissolves, so that absorption of the drug typically occurs at least in part via the oral mucosa. For intraoral administration, the tablet can be placed in or on any part of the mouth, but placement of the tablet in the sublingual or buccal spaces is preferred. The tablet can alternatively be dissolved or dispersed in a liquid vehicle, preferably water, and swallowed as a draft. Tablets of the invention have an unusual speckled appearance. Without being bound by theory, it is believed that during the process of coating the core with an aqueous coating composition comprising gellan gum, dye particles in contact with the coating composition partially dissolve, causing color to "bleed" into the coating at the locus of each such particle. The color then becomes fixed as the coating dries. The speckled pattern is accentuated and rendered even more attractive or elegant by a high gloss surface texture contributed by the gellan gum. As described more My hereinbelow, many variants of the speckled pattern characteristic of tablets of the invention are possible and practicable, adding a new option to the formulator seeking to prepare a readily identifiable tablet. As a further advantage, the speckled pattern of tablets of the invention can obscure any small areas of discoloration that can sometimes result from variation in process conditions. Other features, advantages and benefits of the invention will be apparent from the description that follows. DETAILED DESCRIPTION OF THE INVENTION A tablet of the invention can be a placebo tablet, i. e., containing no drug or other active agent in the core thereof. Preferably a tablet of the invention contains in the core a therapeutically and/or prophylactically useful amount of a drug, more preferably a drug that is advantageously delivered by peroral or intraoral administration. For example, a drug present in the core of a tablet of the invention can be selected from the following illustrative classes: ACE inhibitors; a-adrenergic agonists; ß-adrenergic agonists; a-adrenergic blockers; p-adrenergic blockers (beta blockers); alcohol deterrents; aldose reductase inhibitors; aldosterone antagonists; amino acids; anabolics; analgesics (both narcotic and non-narcotic); anesthetics; anorexics; antacids; anthelmintics; antiacne agents; antiallergics; antiandrogens; antianginal agents; antianxiety agents; antianythmics; antiasthmatics; antibacterial agents and antibiotics; antialopecia and antibaldness agents; antiamebics; antibodies; anticholinergic drugs; anticoagulants and blood thinners; anticolitis drugs; anticonvulsants; anticystitis drugs; antidepressants; antidiabetic agents; antidiarrheals; antidiuretics; antidotes; antiemetics; antiestrogens; antiflatulents; antifungal agents; antigens; antiglaucoma agents; antihistaminics; antihyperactives; antihyperlipoproteinemics; antihypertensives; antihyperthyroid agents; antihypotensives; antihypothyroid agents; anti-infectives; anti-inflarnmatories (both steroidal and nonsteroidal); antimalarial agents; antimigraine agents; antineoplastics; antiobesity agents; antiparkinsonian agents and antidyskinetics; antipneumonia agents; antiprotozoal agents; antipruritics; antipsoriatics; antip.sychotics; antipyretics; antirheumatics; antisecretory agents; anti-shock medications; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulceratives; antiviral agents; anxiolytics; bactericidins; bone densifiers; broncho dilators; calcium channel blockers; carbonic anhydrase inhibitors; cardiotonics and heart stimulants; chemotherapeutics; choleretics; choliriergics; chronic fatigue syndrome medications; CNS stimulants; coagulants; contraceptives; cystic fibrosis medications; decongestants; diuretics; dopamine receptor agonists; dopamine receptor antagonists; enzymes;' estrogens; expectorants; gastric hyperactivity medications; glucocorticoids; hemostatics; HMG CoAreductase inhibitors; hormones; hypnotics; immunomodulators; immunosuppressants; laxatives; medicaments for oral and periodontal diseases; miotics; monoamine oxidase inhibitors; mucolytics; multiple sclerosis medications; muscle relaxants; mydriatics; narcotic antagonists; NMDA receptor antagonists; oligonucleotides; ophthalmic drugs; oxytocics; peptides, polypeptides and proteins; polysaccharides; progestogens; prostaglandins; protease inhibitors; respiratory stimulants; sedatives; serotonin uptake inhibitors; sex hormones including androgens; smoking cessation drugs; smooth muscle relaxants; smooth muscle stimulants; thrombolytics; tranquihzers; urinary acidifiers; urinary incontinence medications; vasodilators; vasoprotectants; and combinations thereof. It will be understood that any reference herein to a particular drug compound includes tautomers, stereoisomers, salts and prodrugs of that compound and is not specific to any one solid state form of the drug. In one embodiment a drug contained in the core of the tablet is a smoking cessation drug, for example nicotine, a nicotine metabolite or a non-nicotine aid to smoking cessation such as bupropion or ibogaine. Illustratively, a smoking cessation drug can be selected from nicotine and metabolites thereof (e.g., cotinine, norcotinine, nornicotine, nicotine N-oxide, cotinine N-oxide, 3-hydroxycotinine and 5-hydroxycotinine), ibogaine, bupropion and metabolites thereof (e.g., the erythro- and threo-amino alcohols of bupropiou, the eiythro-arnino diol of bupropion and hydroxybupropion), lobeline, selegiline, risperidone and its 9-hydroxy metabolite, desmethylselegiline, substituted pyridine derivatives (e.g., l-[(6-chloro-3-pyridinyI)niethyl]-2-imidazolidine, l-[(6-chloro-3-pvridinyl)methyl]-2-imidazothiazole and analogs thereof), methcamylamine, desipramine, fluoxetine, ropinirole, trimethaphan, trimethaphan camsylate, doxepin, 2-(3-cliloropheriyl)-3,5,5-trimethyl-2-morpholinol, anxiolytics (e.g., isovaleramide), y-vinyl GABA (GVG), epibatidine and derivatives thereof, 7-azabicyclo-[2.2.1]-heptane and -heptene compounds, naltrexone, nalmefehe, ketamine, hexamethonium, pentolinium, dihydro-p-erythroidine, erysodine, d-tubocurarine, pempidine, chlorisondarnine, amantadine, hetero-oxy alkanamines, benzylidene- and cinnamylidene-anabasines, azaindole-ethylamine derivatives, N-(pyridinylmethyl)-heterocyclylideneamines and NK-1 receptor antagonists (e.g., 9-bromo-l,2,3,4,5,6-hexahydro-1,5-methano-pyrido[l ,2-a][ 1,5]diazocin-8-one). In another embodiment a drug contained in the core of the tablet is an antibacterial drug. Illustratively such a drug can be an antibiotic, for example an aminoglycoside, amphem'col, ansamycin, carbapenem, cephalosporin, cephamycin, monobactam, oxacephem, penicillin, lincosamide, macrolide, polypeptide or tetracycline; or a synthetic antibacterial, for example a 2,4-diaminopyrimidine, nitromran, oxazolidinone, quinolone or analog thereof, sulfonamide or sulfone. Presently preferred antibacterials include the following illustrative examples: amikacin, azithromycin, cefixime, cefoperazone, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone, chloramphenicol, ciprofloxacin, clindamycin, colistin, domeclocycline, doxycycline,, erythromycin, gentamicin, lincomycin, linezolid, mafenide, methacycline, ruinocycline, neomycin, norfloxacin, ofloxacin, oxytetracycline, pirlimycin, polymyxin B, pyrimethamine, silver sutfadiazine, sulfacetamide, sulfisoxazole, tetracycline, tobramycin, trimethoprim and combinations thereof. In one embodiment an antibacterial drug present in the core of the tablet is an oxazolidinone, for example selected from (tS}-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-l-piperazinyIJphenylJ-2-oxo-5-oxazolidinyljmethyljacetamide (eperezolid), (iS)-N-[[3-[3-fluoro-4-[4-(morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (linezolid), N-[(5iS)-3-[3-fluoro-4-[4-(2-fluoroethyl)-3-oxo-1 -piperazinyl]phenyl-2-oxo-5- oxazolidinyljmethyljacetamide, (5)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide, and(*S)-N-[[3-[5-(4-pyridyl)pyrid-2-yl]-2-'oxo-5-oxazolidinyl]methyl]acetamide hydrochloride. In another embodiment a drug contained in the core of the tablet is an antimigraine agent. Illustratively such an agent is an alkylxanthine, for example caffeine; a dopamine D2 receptor agonist, for example alpiropride or lisuride; a GABAA receptor modulator, for example ganaxolpne; a 5-hydroxytriptamine (5-HT) receptor agonist, for example almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan or zolmitriptan; ergot or a derivative thereof, for example ergotamine or dihydroergotamine; or a vasomodulator, for example dotarizine, fonazine or lomerizine. In another embodiment a drug contained in the core of the tablet is useful in treating or preventing an ophthalmic disorder. Illustratively such an ophthalmic drug can be an antibacterial, for example selected from the classes listed above. Alternatively or in addition, such an ophthalmic drug can illustratively be an antiglaucoma or intraocular pressure lowering agent, such as (a) an a-adrenergic agonist or sympathomimetic, e.g., adrenolone, apraclonidine, brimonidine or dipivefrin; (b) a p-adrenergic blocker, e.g., acebutolol, adaprolol, alprenolol, atenolol, betaxolol, bufetolol, bufuralol, bunitrolol, bunolol, bupranolol, carteolol, carvedilol, cetamolol, dexpropanolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, nifenalol, oxyprenolol, penbutolol, pindolol, practolol, pronethalol, propranolol, sotalol, timolol, tolamolol, toliprolol or vaninolol; (c) a carbonic anhydrase inhibitor, e.g., acetazolamide or dorzolamide; or (d) a prostaglandin or analog thereof, e.g., PGF2tt analogs such as bimatoprost, latanoprost, travoprost and unoprostone isopropyl. Alternatively or in addition, such an ophthalmic drug can illustratively be a miotic, e.g., carbachol, physostigmine or pilocarpine. Alternatively or in addition, such an ophthalmic drug can illustratively be an anti-inflammatory agent, for example an NSAID, more preferably a selective COX-2 inhibitory drug, for example selected from those listed below. In another embodiment a drug contained in the core of the tablet is an analgesic, antipyretic or anti-inflammatory agent, e.g., aceclofenac, acemetacin, e-acetamidocaproic acid, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid (aspirin), 5-adenosylmethioiune, alclofenac, alclometasone, alfentanil, algestone, allylprodine, alrninoprofen, aloxiprin, alphaprodine, aluminum bis(acetylsalicylate), amcinonide, amfenac, aminochlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-4~picoline, aminopropylon, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, arntolmetin guacil, anileridine, antipyrine, antrafenine, apazone, beclomethasone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine, bennoprofen, betamethasone, bezitramide, a-bisabolol, bromfenac, p-biomo acetanilide, 5-bromosalicylic acid acetate, bromosaligenin, bucetiri, bucloxic acid, bucolome, budesonide, bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butophanol, carbamazepine, carbiphene, carprofen, carsalam, celecoxib, chlorobutanol, chloroprednisone, chlorthenoxazin, choline salicylate, cinchophen, cinmetacin, ciramadol, clidanac, clobetasol, clocortolone, clometacin, clonitazene, clonixin, clopirac, cloprednol, clove, codeine, codeine methyl bromide, codeine phosphate, codeine sulfate, cortisone, cortivazol, cropropamide, crotethamide, deflazacort, desomorphine, desonide, desoximetasone, dexamethasone, dexoxadrol, dextromoramide, dezocine, diampromide, diclofenac, difenamizole, difenpirarnide, diflorasone, diflucortolone, diflunisal, difluprednate, dihydrocodeine, dihydrocodeinone enol acetate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprocetyl, dipyrone, ditazol, droxicam, emorfazone, enfenamic acid, enoxolone, epirizole, eptazocine, etersalate, ethenzamide, ethoheptazine, ethoxazene, ethyknethylthiambutene, ethylmorphine, etodolac, etofenamate, etonitazene, etoricoxib, eugenol, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentanyl, fentiazac, fepradinol, feprazone, floctafenine, fluazacort, flucloronide, flufenamic acid, flumethasone, flunisolide, flunixin, flunoxaprofen, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluoresone, fluorometholone, fluperolone, flupirtine, fluprednidene, fluprednisolone, fluproquazone, flurandrenolide, flurbiprofen, formocortal, fosfosal, gentisic acid, glafenine, glucarnetacin, glycol salicylate, guaiazulene, halcinonide, halometasone, haloprednone, hydrocodone, hydrocortamate, hydro cortisone, hydromorphone, hydroxypethidine, ibufenac, ibuprofen, ibuproxam, imidazole salicylate, iudomethacin, indoprofen, isofezolac, isoladol, isomethadone, isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac, /j-lactophenetide, lefetamine, levorphanol, lofentanil, lonazolac, lornoxicam, loxoprofen, lysine acetylsalicylate, mazipredone, meclofenamic acid, medrysone, mefenamic acid, meperidine, meprednisone, rneptazinol, mesalairiine, metazocine, methadone, methotrimeprazine, methylprednisolone, metiazinic acid, metofoline, metopon, mofebutazone, mofezolac, morazone, morphine, morpliine hydro chloride, morphine sulfate, morpholine salicylate, myropliine, nabumetone, nalbuphine, 1 -riaphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone, niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone, normorphine, norpipanone, olsalazine, opium, oxaceprol, oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paramethasone, paranyline, parecoxib, parsalmide, pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine hydro chloride, phenocoll, phenoperidine, phenopyrazoiie, phenyl acetylsalicylate, phenylbutazone, phenyl salicylate, phenyramidol, piketoprofen, piminodine, pipebuzone, piperylone, piprofen, pirazolac, piritramide, piroxicam, pranoprofen, prednicarbate, prednisolone, prednisone, prednival, prednylidene, proglumetacin, proheptazine, promedol, propacetamol, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, rofecoxib, salacetamide, salicin, salicylamide, salicylamide o-acetic acid, salicylic acid, salicylsulfuric acid, salsalate, salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, tropesin, valdecoxib, viminol, xenbucin, ximoprofen, zaltoprofen or zomepirac. In a particular embodiment such a drug is a selective COX-2 inhibitory drug, for example a compound of formula (I): (Formula Removed) or a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein: A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings, preferably a heterocyclyl group selected from pyrazolyl, furanonyl, isoxazolyl, pyridinyl, cyclopentenonyl and pyridazinonyl groups; X is O, S or CH2; n is 0 or 1; R11 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, and is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylaminos arylamino, nitro, alkoxyalkyl, alkylsuhinyl, halo, alkoxy and alkylthio; R12 is methyl, amino or aminocarbonylalkyl; R13 is one or more radicals selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthio alkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, aryltbio alkyl, aryloxyalkyl, ar alkylthio alkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylamino alkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N- arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl and N-alkyl-N-arylaminosulfonyl, R13 being optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylarnino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; and R14 is selected from hydrido and halo. In a preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a compound having the formula (II): (Formula Removed) where R15 is a methyl, amino or imide group, R16 is hydrogen or a C1-4 alkyl or alkoxy group, X is N or CR17 where R17 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups. Preferred such five- to six-membered rings are cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position. In another preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a compound having the formula (III): (Formula Removed) or a prodrug thereof or a pharmaceutically acceptable salt thereof, where X" is O, S or N-lower alkyl; R18 is lower haloalkyl; R19 is hydrogen or halogen; R20 is hydrogen, halogen, lower alkyl, lower alkoxy or haloalkoxy, lower aralkylcarbonyl, lower dialkylarninosulfonyl, lower alkylaminosulfonyl, lower aralkylaminosulfonyl, lower heteroaralkylaminosulfonyl, or 5- or 6- membered nitrogen-containing heterocyclosulfonyl; and R21 and R22 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or aryl. A particularly useful compound of formula (III) is (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1 -benzopyran-3-carboxylic acid. In yet another preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a 5-alkyl-2-arylaminophenylacetic acid or derivative thereof. Particularly useful compounds of this class are 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid and pharmaceutically acceptable salts thereof. Illustratively, celecoxib, deracoxib, valdecoxib, parecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-l-oiie, (5)-6,8-dichloro-2-(trifluoromethyl)-2H-1 -benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-l-butyoxy)-5-[4-(methylsuhconyl)phenyl]-3-(2H)-pyridazinone and salts thereof are useful in compositions of the invention. For example, the selective COX-2 inhibitory drug or prodrug thereof can be selected from celecoxib, valdecoxib, parecoxib, rofecoxib, etoricoxib, (5)-6,8-dichloro-2-(trifluoromethyl)-2H-l-benzopyran-3-carboxylic acid and salts thereof. In another embodiment, a drug contained in the core of the tablet is useful in treatment and/or prevention of sexual dysfunction in male and/or female subjects. Such a drug can illustratively be (a) a phosphodiesterase type 5 (PDE5) inhibitor, e.g., sildenafil, tadalafil or vardenafil, (b) a cyclic GMP phosphodiesterase inhibitor, (c) a cyclic AMP activator, (d) an a-adrenergic antagonist, e.g., phentolamine or yohimbine, or (e) a dopaminergic agonist, e.g., apomorphine. Such a drug can be a compound of formula (V) beloAV. Alternatively, a drug contained in the core of the tablet can be other than a drug useful in treatment and/or prevention of sexual dysfunction. As another alternative, a drug contained in the core of the tablet can be useful in treatment and/or prevention of sexual dysfunction but is other than a compound of formula (V) below. In illustrative compositions a drug useful for example in treatment of Parkinson's disease or sexual dysfunction is present in the core of the tablet and is a compound of formula (V) (Formula Removed) or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are the same or different and are H, C1-6 alkyl (optionally phenyl substituted), C3-5alkenyl or alkynyl or C3-10 cycloalkyl, or where R3 is as above and R1 and R2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, mprpholinyl, 4-methylpiperazinyl or imidazolyl groups; X is H, F, Cl, Br, I, OH,C1-6 alkyl or alkoxy, CN, carboxamide, carboxyl or (C1-6 alkyl)carbonyl; A is CH, CH2, CHF, CHC1, CHBr, CHI, CHCH3, C=O, OS, CSCH3, C=NH, CNH2, CNHCH3, CNHCOOCH3, CNHCN, SO2 or N; B is CH, CH2, CHF, CHC1, CHBr, CHI, OO, N, NH or NCH3, and n is 0 or 1; and D is CH, CH2, CHF, CHC1, CHBr, CHI, C=O, O, N, NH or NCH3. It is preferred that the compound of formula (V) or salt thereof is water-soluble. Pharmaceutically acceptable salts of a compound of formula (V) include without restriction salts of the following acids: hydrochloric, hydrobromic, sulfuric, methanesulfonic, phosphoric, nitric, benzoic, citric, tartaric, fumaric and maleic acids, and mono- and dicarboxylic acids of formula CH3-(CH2)n-COOH and HOOC-(CH2)n-COOH where n is 0 to 4, for example malonic acid. Particularly preferred salts are the hydrochloride salt and the maleate, i.e., (Z)-2-butenedioate, salt. Compounds of formula (V) and their salts can be prepared by processes known per se, including processes described in patent literature cited herein. However, the present invention is not restricted by the process used to prepare the therapeutic agent. Preferred compounds of formula (V) are those disclosed generically or specifically in U.S. Patent No. 5,273,975 to Moon et al. Especially preferred compounds are those of formula (VI) (Formula Removed) wherein X is O or S, and pharmaceutically acceptable salts thereof. Tablet cores useful according to the invention can be prepared by any suitable process known in the art. A core according to the invention comprises a matrix wherein are distributed solid particles of a water-soluble dye. Any suitable excipient or excipients can form the matrix. For peroral tablets the matrix typically comprises a diluent or carrier, for example lactose and/or starch, and can further comprise additional excipients such as binders, disintegrants, wetting agents, etc. For intraoral tablets the matrix typically comprises a water-soluble sugar, for example mannitol and/or maltose. If a drug is present in the core, the drug, too, is distributed in the matrix. The ultimate appearance of the tablet depends in part upon the selection of water-soluble dye and the number and size of the solid particles of the dye. For example, relatively large particles will tend to produce a speckled pattern having larger blocks of color than will be produced by smaller particles; and a relatively large number of particles will tend to produce a speckled pattern where the color covers a greater portion of the tablet surface than will be produced by fewer particles. A more water-soluble dye will tend to produce larger and/or less discrete blocks of color than will be produced by a less water-soluble dye. Optionally solid particles of more than one water-soluble dye can be present in the core, contributing a bicolored or multicolored speckled appearance to the tablet. The core is coated with a coating composition comprising gellan gum, as more fully described below. The coating is typically present in an amount representing a weight gain of about 0.1% to about 5%, but greater or lesser amounts can be used if desired. Preferably the gellan gum constitutes about 25% to 100%, more preferably about 50% to 100%, by weight of the coating. Preferably the coating is an excipient coating. An "excipient coating" herein is a coating consisting, at least at the time 'of application of the coating to the core, only !• of excipient materials, i.e., having substantially no drug present therein. It will be understood that during manufacture and storage some migration of a drug substance can potentially occur from the core to the coating of a tablet of the invention, but this is generally minimal. Thus a drug substance, if present in the tablet, is largely confined to the core where it is not commingled with gellan gum. Any gellan gum can be used in the coating composition, but it is preferred to use a deacylated gellan gum such as that sold under the trademark Kelcogel™. Optionally one or more additional gums and/or biopolymers, for example alginates, can be present in the coating composition. The coating composition comprises a sprayable vehicle, preferably water, having dissolved or dispersed therein a gellan gum and optionally one or more additional excipients. Preferably the coating composition has a total solids concentration of about 1% to about 10% by weight, and a gellan gum concentration of about 1% to about 5% by weight. Additional excipients present in the coating composition can include one or more buffering agents, typically at a concentration of about 0.03% to about 3% by weight; one or more plasticizers, typically at a concentration of about 0.03% to about 3% by weight; and/or one or more dispersing and/or emulsifying agents, typically at a concentration of about 0.03% to about 3% by weight. An example of a suitable buffering agent is sodium citrate. An example of a suitable plasticizer is propylene glycol. An example of a suitable dispersing or emulsifying agent is lecithin. Flavoring agents can also be included in the coating composition if desired. The coating composition can be prepared by any suitable process involving dissolving the gellan gum and other, optional, excipients in the vehicle, preferably water. Order of addition is not critical. The water is preferably heated, for example to a temperature of about 55°C to about 85°C. Gellan gum and other excipients, if present, are added with stirring until all ingredients are homogeneously dispersed. The resulting coating liquid is preferably maintained at an elevated temperature during the stirring and subsequent spraying procedure. Tablet cores to be coated are placed in a suitable coating apparatus, for example a coating pan, and are preferably preheated to a bed temperature of about 50°C to about 70°C. The coating liquid is sprayed on to the tablets under conditions that will be readily optimized by one of skill in the art.. Spraying is continued until an amount of coating solution equivalent to a weight gain of about 0.1% to about 5% has been applied, The resulting coated tablets are preferably cooled to ambient temperature, or about 20°C to about 35°C, prior to discharge from the coating pan. Coating and cooling conditions can also affect the precise color pattern of the finished tablet. For example, if coating is done at lower temperatures and/or if cooling occurs slowly, so that the solid dye particles in the core are exposed to water for a longer period of time, a speckled pattern with larger blocks of color will typically result. An illustrative sublingual tablet of the invention containing as active agent a salt, e.g., the maleate salt, of sumanirole or (R)-5,6-dihydro-5-(methylamino)-4H- imidazo[4,5-ij]-quinohne-2(lH)-thione has a core having the following composition: active agent 0.1-3% free base equivalent mannitol 50-90% powdered sorbitol 10-40% hydroxypropylcellulose 0-10% xanthan gum 0-5% flavoring agent 0-0.5% water-soluble dye 0-0.5% colloidal silicon dioxide 0-1 % magnesium stearate 0.5—5% all percentages being by weight. Another illustrative sublingual tablet of the invention containing as active agent a salt, e.g., the maleate salt, of sumanirole or (R)-5,6-dihydro-5-(methylamino)-4H- imidazo[4,5-ij]-quinoline-2(lH)-thione has a core having the following composition: active agent 0.1-3% free base equivalent lactose monohydrate 50-85% pregelatinized starch 10-45% xanthan gum 0-5% flavoring agent 0-0.5% water-soluble dye 0—0.5% colloidal silicon dioxide 0-1% magnesium stearate 0.5-5% all percentages being by weight. Yet another illustrative sublingual tablet of the invention containing as active agent a salt, e.g., the maleate salt, of sumanirole or (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(lH)-thione has a core having the following composition: active agent 0,1-3 % free base equivalent micro crystalline cellulose 30-70% pregelatinized starch 25-65% croscarmellose sodium 0-10% xanthan gum 0-5% flavoring agent 0-0.5% water-soluble dye 0-0.5% colloidal silicon dioxide 0-1% magnesium stearate 0.5-5% all percentages being by weight. EXAMPLES The following examples illustrate aspects of the present invention but should not be construed as limitations. In these examples "compound Z" refers to (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoUne-2(lH)-thione, maleate salt. All percentages are by weight unless otherwise indicated. Example 1 A sublingual tablet formulation was prepared having the following composition: compound Z 1.11% Avicel™PH-101 (microcrystalline cellulose) 46.71% Starch 1500 of Colorcon (pregelatinized starch) 44.00% croscarmellose sodium NF 5.00% colloidal silicon dioxide NF 0.50% cinnamon flavor 0.14% mint flavor 0.04% dye (cherry shade #1632, Crompton & Knowles) 0.50% magnesium stearate 2.00% Pregelatinized starch and dye were blended in a high-shear mixer for 2 minutes or until homogeneously mixed. The following ingredients were then individually layered over the resulting mixture in the high-shear mixer: compound Z; micro crystalline cellulose; colloidal silicon dioxide; croscarmellose sodium. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the dye was not adequately dispersed throughout the resulting mixture, mixing continued in 1 minute increments until good dispersion of dye was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was added to the high-shear mixer and mixed for 1 minute to form a lubricated tablet stock. The lubricated tablet stock was discharged from the high-shear mixer and stored in desiccated hermetically sealed containers until ready for tabletiug. Tablets were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain tooling with slight curvature to the following specifications: tablet weight 18 0 mg hardness 3-4 SCU friability Example 2 Sublingual tablets prepared as in Example 1 were coated with a gellan gum coating according to the following procedure. A coating liquid having the following composition was prepared: gellan gum (Kelcogel™) 2.00% sodium citrate 0.13% propylene glycol 0.40% lecithin 0.20% deionized water 97.27% Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating liquid having a solids content of 2.73% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure. Tablets of Example 1, in an arribunt of 700 g, were placed in a 12 inch (approximately 300 mm) coating pan and preheated to a bed temperature of 60°C. The coating liquid was sprayed on to the tablets under the following conditions: outlet air temperature 50-60°C pan speed 16rpm air flow 30-35 cfrn (0.84-0.98 mVminute) atomizing air pressure 10psi(69kPa) peristaltic pump setting 15-20 g/minute Spraying was continued until an amount of coating solution equivalent to a weight gain of 1.2% had been applied: The resulting coated tablets were cooled to 30°C prior to discharge from the coating pan. The tablets had an attractive high gloss appearance with cherry red speckles. Example 3 A sublingual tablet formulation was prepared having the following composition: compound Z 1.05% mannitol, granular 70.00% sorbitol 16.57% hydroxypropylcellulose., type LH-11 7.00% xanthan gum 2.50% colloidal silicon dioxide NF 0.50% cinnamon flavor 0.14% mint flavor 0.04% dye (cherry shade #1632, Crompton & Knowles) 0.20% magnesium stearate 2.00% Mannitol and dye were blended in a high-shear mixer for 2 minutes or until homogeneously mixed. The following ingredients were then individually layered over the resulting mixture in the high-shear mixer: compound Z; sorbitol; hydroxypropylcellulose; xanthan gum; colloidal silicon dioxide. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the dye was not adequately dispersed throughout the resulting mixture, mixing continued in 1 minute increments until good dispersion of dye was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was added to the high-shear mixer and mixed for 1 minute to form a lubricated tablet stock. The lubricated tablet stock was discharged from the high-shear mixer and stored in desiccated hermetically sealed containers until ready for tableting. Tablets were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain tooling with slight curvature to the following specifications: tablet weight . 190 mg hardness 3-4 SCU friability Example 4 Sublingual tablets prepared as in Example 3 were coated with a gellan gum coating according to the following procedure. A coating liquid having the following composition was prepared: gellan gum (Kelcogel™) 2.00% sodium citrate 0.13% propylene glycol 0.40% lecithin (Lipoid™ LS-100) 0.20% flavor 0.30% deionized water 96.97% Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating liquid having a solids content of 3.03% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure. Tablets of Example 1, in an amount of 700 g, were placed in a 12 inch (approximately 300 mm) coating pan and preheated to a bed temperature of 60°C. The coating liquid was sprayed on to the tablets under the following conditions: outlet air temperature 50-60°C pan speed 16rpm air flow 30-35 cfrn (0.84-0.98 mVminute) atomizing air pressure 10 psi (69 kPa) peristaltic pump setting 15-20 g/minute Spraying was continued until an amount of coating solution equivalent to a weight gain of 1.36% had been applied. The resulting coated tablets were cooled to 30°C prior to discharge from the coating pan. The tablets had an attractive high gloss appearance with cherry red speckles. Example 5 A sublingual tablet formulation was prepared having the following composition: compound Z 0.43% Avicel™ PH-101 (microcrystalHne cellulose) 47.39% Starch 1500 of Colorcon (pregelatinized starch) 44.00% croscarmellose sodium NF 5.00% colloidal silicon dioxide NF 0.50% cinnamon flavor 0.14% mint flavor 0.04% color (cherry shade #1632, Crompton & Knowles) 0.50% magnesium stearate 2.00% Pregelatinized starch and color were blended in a high-shear mixer for 2 minutes or until homogeneously mixed. The following ingredients were then individually layered over the resulting mixture in the high-shear mixer: compound Z; micro crystalline cellulose; colloidal silicon dioxide; croscarmellose sodium. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the color was not adequately dispersed throughout the resulting mixture, mixing continued in 1 minute increments until good dispersion of color was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was hand screened through a #20 mesh pharmaceutical screen, then added to the high-shear mixer and mixed for 1 minute to form a lubricated tablet stock. The lubricated tablet stock was discharged from the high-shear mixer and stored in desiccated hermetically sealed containers until ready for tableting. Tablets were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain tooling with slight curvature to the following specifications: tablet weight 180 mg hardness 3.5-4 SCU friability Example 6 Sublingual tablets prepared as in Example 5 were coated with-a gellan gum coating according to the following procedure. A coating liquid having the following composition was prepared: gellan gum (Kelcogel™) 2.00% s o dium citrate 0.13% propylene glycol 0.40% lecithin (Lipoid™ LS-100) 0.20% hot cinnamon flavor 0.30% deionized water 96.97% Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating liquid having a solids content of 3.03% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure. Tablets of Example 5, in an amount of 7000 g, were placed in a 24 inch (approximately 600 mm) coating pan and preheated to a bed temperature of 60°C. The coating liquid was sprayed on to the tablets under the following conditions: outlet air temperature 48—55°C pan speed 10—14 rpm, preferably 14 rpm air flow 300-400 cfrn (8.5-11.3 mVminute) atomizing air pressure 20-35 psi (138-242 kPa), preferably about 20 psi peristaltic pump setting 15-40 g/minute/gun (2 gun spray system), preferably 30-40 g/minute/gun tablet bed temp 37-50°C, preferably about 40°C Spraying was continued until an amount of coating solution equivalent to a weight gain of 2.04% had been applied. The resulting coated tablets were cooled to 30°C prior to discharge from the coating pan. The tablets had an attractive high gloss appearance with cherry red speckles. WE CLAIM: 1. A pharmaceutical tablet comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum; and wherein the core comprises a drug in a therapeutically and/or prophylactically effective amount. 2. The tablet as claimed in claim 1 having a speckled surface appearance. 3. The tablet as claimed in claim 1 wherein the drug is selected from the group consisting of ACE inhibitors; a-adrenergic agonists; ß- adrenergic agonists; a-adrenergic blockers; ß-adrenergic blockers; alcohol deterrents; aldose reductase inhibitors; aldosterone antagonists; amino acids; anabolics; analgesics (both narcotic and non-narcotic); anesthetics; anorexics; antacids; anthelmintics; antiacne agents; antiallergics; antiandrogens; antianginal agents; antianxiety agents; antiarrythmics; antiasthmatics; antibacterial agents and antibiotics; antialopecia and antibaldness agents; antiamebics; antibodies; anticholinergic drugs; anticoagulants and blood thinners; anticolitis drugs; anticonvulsants; anticystitis drugs; antidepressants; antidiabetic agents; antidiarrheals; antidiuretics; antidotes; antiemetics; antiestrogens; antiflatulents; antifungal agents; antigens; antiglaucoma agents; antihistaminics; antihyperactives; antihyperlipoproteinemics; antihypertensives; antihyperthyroid agents; antihypotensives; antihypothyroid agents; anti-infectives; anti-inflammatories (both steroidal and nonsteroidal) antimalarial agents; antimigraine agents; antineoplastics; antiobesity agents; antiparkinsonian agents and antidyskinetics; antipneumonia agents; antiprotozoal agents; antipruritics; antipsoriatics; antipsychotics; antipyretics; antirheumatics; antisecretory agents; anti-shock medications; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulceratives; antiviral agents; anxiolytics; bactericidins; bone densifiers; bronchodilators; calcium channel blockers; carbonic anhydrase inhibitors; cardiotonics and heart stimulants; chemotherapeutics; choleretics; cholinergics; chronic fatigue syndrome medications; CNS stimulants; coagulants; contraceptives; cystic fibrosis medications; decongestants; diuretics; dopamine receptor agonists; dopamine receptor antagonists; enzymes; estrogens; expectorants; gastric hyperactivity medications; glucocorticoids; hemostatics; HMG CoA reductase inhibitors; hormones; hypnotics; immunomodulators; immunosuppressants; laxatives; medicaments for oral and periodontal diseases; miotics; monoamine oxidase inhibitors; mucolytics; multiple sclerosis medications; muscle relaxants; mydriatics; narcotic antagonists; NMDA receptor antagonists; oligonucleotides; ophthalmic drugs; oxytocics; peptides, polypeptides and proteins; polysaccharides; progestogens; prostaglandins; protease inhibitors; respiratory stimulants; sedatives; serotonin uptake inhibitors; sex hormones including androgens; smoking cessation drugs; smooth muscle relaxants; smooth muscle stimulants; thrombolytics; tranquilizers; urinary acidifiers; urinary incontinence medications; vasodilators; vasoprotectants; and combinations thereof. 4. The tablet as claimed in claim 1 wherein the drug is a smoking cessation drug. 5. The tablet as claimed in claim 4 wherein the smoking cessation drug is selected from bupropion, ibogaine, nicotine and metabolites thereof. 6. The tablet as claimed in claim 1 wherein the drug is an antibacterial drug. 7. The tablet as claimed in claim 6 wherein the antibacterial drug is x an oxazolidinone. 8. The tablet as claimed in claim 7 wherein the oxazolidinone is selected from eperezolid, linezolid, N-[(5S) -3-[3-fluoro-4-[4-(2- fluoroethyl)-3-oxo-1 -piperazinyl]phenyl-2-oxo-5- oxazolidinyl]methyl]acetamide, (S)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide, and (S)-N-[[3-[5)-(4-pyridyl)pyrid-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride. 9. The tablet as claimed in claim 1 wherein the drug is an antimigraine agent. 10. The tablet as claimed in claim 9 wherein the antimigraine agent is a 5-HT receptor agonist. 11. The tablet as claimed in claim 10 wherein the 5-HT receptor agonist is selected from the group consisting of almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan or zolmitriptan. 12. The tablet as claimed in claim 1 wherein the drug is an antiglaucoma or intraocular pressure lowering agent. 13. The tablet as claimed in claim 12 wherein the antiglaucoma or intraocular pressure lowering agent is selected from the group consisting of adrenolone, apraclonidine, brimonidine, dipivefrin, acebutolol, adaprolol, alprenolol, atenolol, betaxolol, bufetolol, bufuralol, bunitrolol, bunolol, bupranolol, carteolol, carvedilol, cetamolol, dexpropanolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, nifenalol, oxyprenolol, penbutolol, pindolol, practolol, pronethalol, propranolol, sotalol, timolol, tolamolol, toliprolol, vaninolol, acetazolamide, dorzolamide, bimatoprost, latanoprost, travoprost, unoprostone isopropyl and combinations thereof. 14. The tablet as claimed in claim 1 wherein the drug is an analgesic, antipyretic or anti-inflammatory agent. 15. The tablet as claimed in claim 14 wherein the analgesic, antipyretic or anti-inflammatory agent is selected from the group consisting of aceclofenac, acemetacin, e-acetamidocaproic acid, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid, S- adenosylmethionine, alclofenac, alclometasone, alfentanil, algestone, allylprodine, alminoprofen, aloxiprin, alphaprodine, aluminum bis(acetylsalicylate), amcinonide amfenac, aminochlorthenoxazin, 3- amino-4-hydroxybutyric acid, 2-amino-4-picoline, aminopropylon, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, amtolmetin guacil, anileridine, antipyrine, antrafenine, apazone, beclomethasone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine, bermoprofen, betamethasone, bezitramide, a-bisabolol, bromfenac, p-bromoacetanilide, 5- bromosalicylic acid acetate, bromosaligenin, bucetin, bucloxic acid, bucolome, budesonide, bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butophanol, carbamazepine, carbiphene, carprofen, carsalam, celecoxib, chlorobutanol, chloroprednisone, chlorthenoxazin, choline salicylate, cinchophen, cinmetacin, ciramadol, clidanac, clobetasol, clocortolone, clometacin, clonitazene, clonixin, clopirac, cloprednol, clove, codeine, codeine methyl bromide, codeine phosphate, codeine sulfate, cortisone, cortivazol, cropropamide, crotethamide, deflazacort, desomorphine, desonide, desoximetasone, dexamethasone, dexoxadrol, dextromoramide, dezocine, diampromide, diclofenac, difenamizole, difenpiramide, diflorasone, diflucortolone, diflunisal, difluprednate, dihydrocodeine, dihydrocodeinone enol acetate, dihydrornorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprocetyl, dipyrone, ditazol, droxicam, emorfazone, enfenamic acid, enoxolone, epirizole, eptazocine, etersalate, ethenzamide, ethoheptazine, ethoxazene, ethylmethylthiambutene, ethylmorphine, etodolac, etofenarnate, etonitazene, etoricoxib, eugenol, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentanyl, fentiazac, fepradinol, feprazone, floctafenine, fluazacort, flucloronide, flufenamic acid, flumethasone, flunisolide, flunixin, flunoxaprofen, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluoresone, fluorometholone, fluperolone, flupirtine, fluprednidene, fluprednisolone, fluproquazone, flurandrenolide, flurbiprofen, formocortal, fosfosal, gentisic acid, glafenine, glucametacin, glycol salicylate, guaiazulene, halcinonide, halometasone, haloprednone, hydrocodone, hydrocortamate, hydrocortisone, hydromorphone, hydroxypethidine, ibufenac, ibuprofen, ibuproxam, imidazole salicylate. indomethacin, indoprofen, isofezolac, isoladol, isomethadone, isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac, p-lactophenetide, lefetamine, levorphanol, lofentanil, lonazolac, lornoxicam, loxoprofen, lysine acetylsalicylate, mazipredone, meclofenamic acid, medrysone, mefenamic acid, meperidine, meprednisone, meptazinol, mesalamine, metazocine, methadone, methotrimeprazine, methylprednisolone, metiazinic acid, metofoline, metopon, mofebutazone, mofezolac, morazone, morphine, morphine hydrochloride, morphine sulfate, morpholine salicylate, myrophine, nabumetone, nalbuphine, 1-naphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone, niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone, normorphine, norpipanone, olsalazine, opium, oxaceprol, oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paramethasone, paranyline, parecoxib, parsalmide, pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine hydrochloride, phenocoll, phenoperidine, phenopyrazone, phenyl acetylsalicylate, phenylbutazone, phenyl salicylate, phenyrarmidol, piketoprofen, piminodine, pipebuzone, piperylone, piprofen, pirazolac, piritramide, piroxicam, pranoprofen, prednicarbate, prednisolone, prednisone, prednival, prednylidene, progiumetacin, proheptazine, promedol, propacetamol, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, rofecoxib, salacetamide, salicin, salicylamide, salicylamide o-acetic acid, salicylic acid, salicylsulfuric acid, salsalate, salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, tropesin, valdecoxib, viminol, xenbucin, ximoprofen, zaltoprofen and zomepirac. 16. The tablet as claimed in claim 14 wherein the analgesic, antipyretic or anti-inflammatory agent is a selective COX-2 inhibitory drug. 17. The tablet as claimed in claim 16 wherein the selective COX-2 inhibitory drug is a compound having the formula (Formula Removed) where R15 is a methyl, amino or imide group, R16 is hydrogen or a Ci-4 alkyl or alkoxy group, X is N or CR17 where R17 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups. 18. The tablet as claimed in claim 16 wherein the selective COX-2 inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, parecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]-2-cyclopenten-1- one, (S)-6,8-dichloro-2- (trifluoromethyl)-2H-l-benzopyran-3-carboxylic acid, 2-(3,4- difluorophenyl)-4-(3-hydroxy-3-methyl-1-butyoxy)-5-[4- (methylsulfonyl)phenyl]-3-(2H)-pyridazinone and salts thereof. 19. The tablet as claimed in claim 1 wherein the drug is an agent selected from the group consisting of PDE5 inhibitors, cyclic AMP activators, a-adrenergic antagonists and dopaminergic agonists. 20. The tablet as claimed in claim 19 wherein the agent is a compound of formula (Formula Removed) or a pharmaceutically acceptable salt thereof; wherein R1, R2 and R3 are the same or different and are H, C1-6 alkyl (optionally phenyl substituted), C3-5 alkenyl or alkyayl or C3-10 cycloalkyl, or where R3 is as above and R1 and R2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups; X is H, F, Cl, Br, I, OH, C1-6 alkyl or alkoxy, CN, carboxamide, carboxyl or (C1-6 alkyl) carbonyl; A is CH, CH2, CHF, CHCl, CHBr, CHI, CHCH3, C=O, C=S, CSCH3, C=NH, CNH2, CNHCH3, CNHCOOCH3, CNHCN, SO2 or N; B is CH, CH2, CHF, CHCl, CHBr, CHI, C=O, N, NH or NCH3 and n is 0 or 1; and D is CH, CH2, CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH3. 21. The tablet as claimed in 19 wherein the agent is a compound of formula (Formula Removed) wherein X is O or S, or a pharmaceutically acceptable salt thereof. 22. The tablet as claimed in claim 1 wherein the coating is present in an amount representing a weight gain of 0.1% to 5%. 23. The tablet as claimed in claim 1 wherein the gellan gum constitutes 25% to 100% by weight of the coating. 24. The tablet as claimed in claim 1 wherein the gellan gum constitutes 50% to 100% by weight of the coating. 25. The tablet as claimed in claim 1 wherein the coating further comprises at least one additional excipient selected from the group consisting of buffering agents, plasticizers and dispersing and emulsifying agents.

Full Text

PHARMACEUTICAL TABLET
FIELD OF THE INVENTION
The present invention relates to orally deliverable pharmaceutical dosage forms, more particularly tablets.
BACKGROUND OF THE INVENTION
Tablets are the most common and convenient pharmaceutical dosage form for oral administration of medications. It is an important functional attribute of a tablet that it be readily identifiable by appearance, including by size, shape, surface texture, markings and color. Such ready identifiability is important in minimizing dispensing errors and in enabling patients on multiple medication to distinguish among the drugs they take at different times or frequencies. A vast array of drugs are now formulated as tablets, many of these drugs being formulated at different dosage strengths, and it is therefore becoming ever more important, yet ever more difficult to insure, that any new tablet has unique appearance.
In particular, the range of readily distinguishable colors available to the formulator of tablets is rather limited. To some extent this problem has been alleviated by use of particolored, bicolored or multicolored tablets. However, a need remains in the art for tablets having unique surface color patterns.
In the case of coated tablets, color can be an attribute of the surface coating. For example, a range of opaque pigments are available for incorporation in tablet coating compositions such as those based on ethylcellulose; these pigments tend to impart a solid white or colored appearance to a coated tablet. Alternatively, the surface coating can be clear and transparent, and the color of the coated tablet is controlled by the color of the tablet core underlying the coating.
U.S. Patent No. 6,326,028 to Nivaggioli et al, incorporated herein by reference, discloses a tablet coating comprising gellan gum. Such a coating is said to be useful for tablets to be taken orally, and to confer benefits in appearance, identification, mouth feel, reduced dust, stability, color and/or swallowability.
International Patent Publication No. WO 01/10406, incorporated herein by reference, discloses compositions said to be suitable for a wide range of routes of administration of sildenafil citrate, including buccal and sublignual routes. Preferred
compositions disclosed are said to comprise a solution, gel, semisolid, suspension, metered dose device, transdermal patch or film. It is indicated that such compositions can include a gelling system, for example gellan gum 0.5% to 10%.
International Patent Publication No. WO 02/05820, incorporated herein by reference, discloses film dosage forms comprising sildenafil citrate. These dosage forms are prepared by mixing a solid dispersion of sildenafil citrate and a water-soluble sugar with a hydrocolloid and optionally other ingredients, and are said, upon placement on a mucosal surface, to form a coating that subsequently disintegrates and dissolves to release sildenafil. Gellan sodium salt is listed among hydrocolloids said to be useful in such film dosage forms.
U.S. Patent No. 6,291,506 to Levin, incorporated herein by reference, discloses that the ophthalmic drug carvedilol can be formulated for ocular administration by suspending it in an agent such as gellan gum that will increase corneal contact time with the drug. Other possible delivery modes for the drug are contemplated therein. A claim is included to a method wherein the drug is delivered by a selection of routes including sublingually.
SUMMARY OF THE INVENTION
There is now provided a pharmaceutical tablet comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum.
The tablet is particularly suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, illustratively a human subject. The term "peroral" herein refers to administration via the mouth involving swallowing of the tablet without substantial prior disintegration of the tablet in the mouth, so that absorption of the drug typically occurs in the gastrointestinal tract. The term "intraoral" herein refers to administration by placement of the tablet in the mouth of the subject, where the tablet disintegrates and/or dissolves, so that absorption of the drug typically occurs at least in part via the oral mucosa. For intraoral administration, the tablet can be placed in or on any part of the mouth, but placement of the tablet in the sublingual or buccal spaces is preferred.
The tablet can alternatively be dissolved or dispersed in a liquid vehicle, preferably water, and swallowed as a draft.
Tablets of the invention have an unusual speckled appearance. Without being bound by theory, it is believed that during the process of coating the core with an aqueous coating composition comprising gellan gum, dye particles in contact with the coating composition partially dissolve, causing color to "bleed" into the coating at the locus of each such particle. The color then becomes fixed as the coating dries. The speckled pattern is accentuated and rendered even more attractive or elegant by a high gloss surface texture contributed by the gellan gum. As described more My hereinbelow, many variants of the speckled pattern characteristic of tablets of the invention are possible and practicable, adding a new option to the formulator seeking to prepare a readily identifiable tablet.
As a further advantage, the speckled pattern of tablets of the invention can obscure any small areas of discoloration that can sometimes result from variation in process conditions.
Other features, advantages and benefits of the invention will be apparent from the description that follows.
DETAILED DESCRIPTION OF THE INVENTION A tablet of the invention can be a placebo tablet, i. e., containing no drug or other active agent in the core thereof. Preferably a tablet of the invention contains in the core a therapeutically and/or prophylactically useful amount of a drug, more preferably a drug that is advantageously delivered by peroral or intraoral administration.
For example, a drug present in the core of a tablet of the invention can be selected from the following illustrative classes: ACE inhibitors; a-adrenergic agonists; ß-adrenergic agonists; a-adrenergic blockers; p-adrenergic blockers (beta blockers); alcohol deterrents; aldose reductase inhibitors; aldosterone antagonists; amino acids; anabolics; analgesics (both narcotic and non-narcotic); anesthetics; anorexics; antacids; anthelmintics; antiacne agents; antiallergics; antiandrogens; antianginal agents; antianxiety agents; antianythmics; antiasthmatics; antibacterial agents and antibiotics; antialopecia and antibaldness agents; antiamebics; antibodies; anticholinergic drugs; anticoagulants and blood thinners; anticolitis drugs; anticonvulsants; anticystitis drugs; antidepressants; antidiabetic agents; antidiarrheals; antidiuretics; antidotes; antiemetics; antiestrogens; antiflatulents; antifungal agents; antigens; antiglaucoma agents;
antihistaminics; antihyperactives; antihyperlipoproteinemics; antihypertensives; antihyperthyroid agents; antihypotensives; antihypothyroid agents; anti-infectives; anti-inflarnmatories (both steroidal and nonsteroidal); antimalarial agents; antimigraine agents; antineoplastics; antiobesity agents; antiparkinsonian agents and antidyskinetics; antipneumonia agents; antiprotozoal agents; antipruritics; antipsoriatics; antip.sychotics; antipyretics; antirheumatics; antisecretory agents; anti-shock medications; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulceratives; antiviral agents; anxiolytics; bactericidins; bone densifiers; broncho dilators; calcium channel blockers; carbonic anhydrase inhibitors; cardiotonics and heart stimulants; chemotherapeutics; choleretics; choliriergics; chronic fatigue syndrome medications; CNS stimulants; coagulants; contraceptives; cystic fibrosis medications; decongestants; diuretics; dopamine receptor agonists; dopamine receptor antagonists; enzymes;' estrogens; expectorants; gastric hyperactivity medications; glucocorticoids; hemostatics; HMG CoAreductase inhibitors; hormones; hypnotics; immunomodulators; immunosuppressants; laxatives; medicaments for oral and periodontal diseases; miotics; monoamine oxidase inhibitors; mucolytics; multiple sclerosis medications; muscle relaxants; mydriatics; narcotic antagonists; NMDA receptor antagonists; oligonucleotides; ophthalmic drugs; oxytocics; peptides, polypeptides and proteins; polysaccharides; progestogens; prostaglandins; protease inhibitors; respiratory stimulants; sedatives; serotonin uptake inhibitors; sex hormones including androgens; smoking cessation drugs; smooth muscle relaxants; smooth muscle stimulants; thrombolytics; tranquihzers; urinary acidifiers; urinary incontinence medications; vasodilators; vasoprotectants; and combinations thereof.
It will be understood that any reference herein to a particular drug compound includes tautomers, stereoisomers, salts and prodrugs of that compound and is not specific to any one solid state form of the drug.
In one embodiment a drug contained in the core of the tablet is a smoking cessation drug, for example nicotine, a nicotine metabolite or a non-nicotine aid to smoking cessation such as bupropion or ibogaine.
Illustratively, a smoking cessation drug can be selected from nicotine and metabolites thereof (e.g., cotinine, norcotinine, nornicotine, nicotine N-oxide, cotinine N-oxide, 3-hydroxycotinine and 5-hydroxycotinine), ibogaine, bupropion and
metabolites thereof (e.g., the erythro- and threo-amino alcohols of bupropiou, the eiythro-arnino diol of bupropion and hydroxybupropion), lobeline, selegiline, risperidone and its 9-hydroxy metabolite, desmethylselegiline, substituted pyridine derivatives (e.g., l-[(6-chloro-3-pyridinyI)niethyl]-2-imidazolidine, l-[(6-chloro-3-pvridinyl)methyl]-2-imidazothiazole and analogs thereof), methcamylamine, desipramine, fluoxetine, ropinirole, trimethaphan, trimethaphan camsylate, doxepin, 2-(3-cliloropheriyl)-3,5,5-trimethyl-2-morpholinol, anxiolytics (e.g., isovaleramide), y-vinyl GABA (GVG), epibatidine and derivatives thereof, 7-azabicyclo-[2.2.1]-heptane and -heptene compounds, naltrexone, nalmefehe, ketamine, hexamethonium, pentolinium, dihydro-p-erythroidine, erysodine, d-tubocurarine, pempidine, chlorisondarnine, amantadine, hetero-oxy alkanamines, benzylidene- and cinnamylidene-anabasines, azaindole-ethylamine derivatives, N-(pyridinylmethyl)-heterocyclylideneamines and NK-1 receptor antagonists (e.g., 9-bromo-l,2,3,4,5,6-hexahydro-1,5-methano-pyrido[l ,2-a][ 1,5]diazocin-8-one).
In another embodiment a drug contained in the core of the tablet is an antibacterial drug. Illustratively such a drug can be an antibiotic, for example an aminoglycoside, amphem'col, ansamycin, carbapenem, cephalosporin, cephamycin, monobactam, oxacephem, penicillin, lincosamide, macrolide, polypeptide or tetracycline; or a synthetic antibacterial, for example a 2,4-diaminopyrimidine, nitromran, oxazolidinone, quinolone or analog thereof, sulfonamide or sulfone. Presently preferred antibacterials include the following illustrative examples: amikacin, azithromycin, cefixime, cefoperazone, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone, chloramphenicol, ciprofloxacin, clindamycin, colistin, domeclocycline, doxycycline,, erythromycin, gentamicin, lincomycin, linezolid, mafenide, methacycline, ruinocycline, neomycin, norfloxacin, ofloxacin, oxytetracycline, pirlimycin, polymyxin B, pyrimethamine, silver sutfadiazine, sulfacetamide, sulfisoxazole, tetracycline, tobramycin, trimethoprim and combinations thereof. In one embodiment an antibacterial drug present in the core of the tablet is an oxazolidinone, for example selected from (tS}-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-l-piperazinyIJphenylJ-2-oxo-5-oxazolidinyljmethyljacetamide (eperezolid), (iS)-N-[[3-[3-fluoro-4-[4-(morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (linezolid), N-[(5iS)-3-[3-fluoro-4-[4-(2-fluoroethyl)-3-oxo-1 -piperazinyl]phenyl-2-oxo-5-
oxazolidinyljmethyljacetamide, (5)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide, and(*S)-N-[[3-[5-(4-pyridyl)pyrid-2-yl]-2-'oxo-5-oxazolidinyl]methyl]acetamide hydrochloride.
In another embodiment a drug contained in the core of the tablet is an antimigraine agent. Illustratively such an agent is an alkylxanthine, for example caffeine; a dopamine D2 receptor agonist, for example alpiropride or lisuride; a GABAA receptor modulator, for example ganaxolpne; a 5-hydroxytriptamine (5-HT) receptor agonist, for example almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan or zolmitriptan; ergot or a derivative thereof, for example ergotamine or dihydroergotamine; or a vasomodulator, for example dotarizine, fonazine or lomerizine.
In another embodiment a drug contained in the core of the tablet is useful in treating or preventing an ophthalmic disorder.
Illustratively such an ophthalmic drug can be an antibacterial, for example selected from the classes listed above.
Alternatively or in addition, such an ophthalmic drug can illustratively be an antiglaucoma or intraocular pressure lowering agent, such as (a) an a-adrenergic agonist or sympathomimetic, e.g., adrenolone, apraclonidine, brimonidine or dipivefrin; (b) a p-adrenergic blocker, e.g., acebutolol, adaprolol, alprenolol, atenolol, betaxolol, bufetolol, bufuralol, bunitrolol, bunolol, bupranolol, carteolol, carvedilol, cetamolol, dexpropanolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, nifenalol, oxyprenolol, penbutolol, pindolol, practolol, pronethalol, propranolol, sotalol, timolol, tolamolol, toliprolol or vaninolol; (c) a carbonic anhydrase inhibitor, e.g., acetazolamide or dorzolamide; or (d) a prostaglandin or analog thereof, e.g., PGF2tt analogs such as bimatoprost, latanoprost, travoprost and unoprostone isopropyl.
Alternatively or in addition, such an ophthalmic drug can illustratively be a miotic, e.g., carbachol, physostigmine or pilocarpine.
Alternatively or in addition, such an ophthalmic drug can illustratively be an anti-inflammatory agent, for example an NSAID, more preferably a selective COX-2 inhibitory drug, for example selected from those listed below.
In another embodiment a drug contained in the core of the tablet is an analgesic, antipyretic or anti-inflammatory agent, e.g., aceclofenac, acemetacin,
e-acetamidocaproic acid, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid (aspirin), 5-adenosylmethioiune, alclofenac, alclometasone, alfentanil, algestone, allylprodine, alrninoprofen, aloxiprin, alphaprodine, aluminum bis(acetylsalicylate), amcinonide, amfenac, aminochlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-4~picoline, aminopropylon, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, arntolmetin guacil, anileridine, antipyrine, antrafenine, apazone, beclomethasone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine, bennoprofen, betamethasone, bezitramide, a-bisabolol, bromfenac, p-biomo acetanilide, 5-bromosalicylic acid acetate, bromosaligenin, bucetiri, bucloxic acid, bucolome, budesonide, bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butophanol, carbamazepine, carbiphene, carprofen, carsalam, celecoxib, chlorobutanol, chloroprednisone, chlorthenoxazin, choline salicylate, cinchophen, cinmetacin, ciramadol, clidanac, clobetasol, clocortolone, clometacin, clonitazene, clonixin, clopirac, cloprednol, clove, codeine, codeine methyl bromide, codeine phosphate, codeine sulfate, cortisone, cortivazol, cropropamide, crotethamide, deflazacort, desomorphine, desonide, desoximetasone, dexamethasone, dexoxadrol, dextromoramide, dezocine, diampromide, diclofenac, difenamizole, difenpirarnide, diflorasone, diflucortolone, diflunisal, difluprednate, dihydrocodeine, dihydrocodeinone enol acetate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprocetyl, dipyrone, ditazol, droxicam, emorfazone, enfenamic acid, enoxolone, epirizole, eptazocine, etersalate, ethenzamide, ethoheptazine, ethoxazene, ethyknethylthiambutene, ethylmorphine, etodolac, etofenamate, etonitazene, etoricoxib, eugenol, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentanyl, fentiazac, fepradinol, feprazone, floctafenine, fluazacort, flucloronide, flufenamic acid, flumethasone, flunisolide, flunixin, flunoxaprofen, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluoresone, fluorometholone, fluperolone, flupirtine, fluprednidene, fluprednisolone, fluproquazone, flurandrenolide, flurbiprofen, formocortal, fosfosal, gentisic acid, glafenine, glucarnetacin, glycol salicylate, guaiazulene, halcinonide, halometasone, haloprednone, hydrocodone, hydrocortamate, hydro cortisone, hydromorphone, hydroxypethidine, ibufenac, ibuprofen, ibuproxam, imidazole salicylate, iudomethacin, indoprofen, isofezolac, isoladol, isomethadone,
isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac, /j-lactophenetide, lefetamine, levorphanol, lofentanil, lonazolac, lornoxicam, loxoprofen, lysine acetylsalicylate, mazipredone, meclofenamic acid, medrysone, mefenamic acid, meperidine, meprednisone, rneptazinol, mesalairiine, metazocine, methadone, methotrimeprazine, methylprednisolone, metiazinic acid, metofoline, metopon, mofebutazone, mofezolac, morazone, morphine, morpliine hydro chloride, morphine sulfate, morpholine salicylate, myropliine, nabumetone, nalbuphine, 1 -riaphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone, niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone, normorphine, norpipanone, olsalazine, opium, oxaceprol, oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paramethasone, paranyline, parecoxib, parsalmide, pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine hydro chloride, phenocoll, phenoperidine, phenopyrazoiie, phenyl acetylsalicylate, phenylbutazone, phenyl salicylate, phenyramidol, piketoprofen, piminodine, pipebuzone, piperylone, piprofen, pirazolac, piritramide, piroxicam, pranoprofen, prednicarbate, prednisolone, prednisone, prednival, prednylidene, proglumetacin, proheptazine, promedol, propacetamol, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, rofecoxib, salacetamide, salicin, salicylamide, salicylamide o-acetic acid, salicylic acid, salicylsulfuric acid, salsalate, salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, tropesin, valdecoxib, viminol, xenbucin, ximoprofen, zaltoprofen or zomepirac.
In a particular embodiment such a drug is a selective COX-2 inhibitory drug, for example a compound of formula (I):
(Formula Removed)
or a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein: A is a substituent selected from partially unsaturated or unsaturated
heterocyclyl and partially unsaturated or unsaturated carbocyclic rings, preferably a heterocyclyl group selected from pyrazolyl, furanonyl, isoxazolyl, pyridinyl, cyclopentenonyl and pyridazinonyl groups; X is O, S or CH2; n is 0 or 1; R11 is at least one substituent selected from heterocyclyl, cycloalkyl,
cycloalkenyl and aryl, and is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylaminos arylamino, nitro, alkoxyalkyl, alkylsuhinyl, halo, alkoxy and alkylthio;
R12 is methyl, amino or aminocarbonylalkyl;
R13 is one or more radicals selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthio alkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, aryltbio alkyl, aryloxyalkyl, ar alkylthio alkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylamino alkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-

arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl and N-alkyl-N-arylaminosulfonyl, R13 being optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylarnino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; and
R14 is selected from hydrido and halo.
In a preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a compound having the formula (II):
(Formula Removed)
where R15 is a methyl, amino or imide group, R16 is hydrogen or a C1-4 alkyl or alkoxy group, X is N or CR17 where R17 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups. Preferred such five- to six-membered rings are cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.
In another preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a compound having the formula (III):

(Formula Removed)
or a prodrug thereof or a pharmaceutically acceptable salt thereof, where X" is O, S or N-lower alkyl; R18 is lower haloalkyl; R19 is hydrogen or halogen; R20 is hydrogen,

halogen, lower alkyl, lower alkoxy or haloalkoxy, lower aralkylcarbonyl, lower dialkylarninosulfonyl, lower alkylaminosulfonyl, lower aralkylaminosulfonyl, lower heteroaralkylaminosulfonyl, or 5- or 6- membered nitrogen-containing heterocyclosulfonyl; and R21 and R22 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or aryl.
A particularly useful compound of formula (III) is (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1 -benzopyran-3-carboxylic acid. In yet another preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a 5-alkyl-2-arylaminophenylacetic acid or derivative thereof. Particularly useful compounds of this class are 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid and pharmaceutically acceptable salts thereof. Illustratively, celecoxib, deracoxib, valdecoxib, parecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-l-oiie, (5)-6,8-dichloro-2-(trifluoromethyl)-2H-1 -benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-l-butyoxy)-5-[4-(methylsuhconyl)phenyl]-3-(2H)-pyridazinone and salts thereof are useful in compositions of the invention.
For example, the selective COX-2 inhibitory drug or prodrug thereof can be selected from celecoxib, valdecoxib, parecoxib, rofecoxib, etoricoxib, (5)-6,8-dichloro-2-(trifluoromethyl)-2H-l-benzopyran-3-carboxylic acid and salts thereof.
In another embodiment, a drug contained in the core of the tablet is useful in treatment and/or prevention of sexual dysfunction in male and/or female subjects. Such a drug can illustratively be (a) a phosphodiesterase type 5 (PDE5) inhibitor, e.g., sildenafil, tadalafil or vardenafil, (b) a cyclic GMP phosphodiesterase inhibitor, (c) a cyclic AMP activator, (d) an a-adrenergic antagonist, e.g., phentolamine or yohimbine, or (e) a dopaminergic agonist, e.g., apomorphine. Such a drug can be a compound of formula (V) beloAV. Alternatively, a drug contained in the core of the tablet can be other than a drug useful in treatment and/or prevention of sexual dysfunction. As another alternative, a drug contained in the core of the tablet can be useful in treatment and/or prevention of sexual dysfunction but is other than a compound of formula (V) below.
In illustrative compositions a drug useful for example in treatment of Parkinson's disease or sexual dysfunction is present in the core of the tablet and is a

compound of formula (V)
(Formula Removed)
or a pharmaceutically acceptable salt thereof, wherein
R1, R2 and R3 are the same or different and are H, C1-6 alkyl (optionally phenyl substituted), C3-5alkenyl or alkynyl or C3-10 cycloalkyl, or where R3 is as above and R1 and R2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, mprpholinyl, 4-methylpiperazinyl or imidazolyl groups; X is H, F, Cl, Br, I, OH,C1-6 alkyl or alkoxy, CN, carboxamide, carboxyl or
(C1-6 alkyl)carbonyl; A is CH, CH2, CHF, CHC1, CHBr, CHI, CHCH3, C=O, OS, CSCH3, C=NH,
CNH2, CNHCH3, CNHCOOCH3, CNHCN, SO2 or N; B is CH, CH2, CHF, CHC1, CHBr, CHI, OO, N, NH or NCH3, and n is 0 or
1; and
D is CH, CH2, CHF, CHC1, CHBr, CHI, C=O, O, N, NH or NCH3. It is preferred that the compound of formula (V) or salt thereof is water-soluble. Pharmaceutically acceptable salts of a compound of formula (V) include without restriction salts of the following acids: hydrochloric, hydrobromic, sulfuric, methanesulfonic, phosphoric, nitric, benzoic, citric, tartaric, fumaric and maleic acids, and mono- and dicarboxylic acids of formula CH3-(CH2)n-COOH and HOOC-(CH2)n-COOH where n is 0 to 4, for example malonic acid.
Particularly preferred salts are the hydrochloride salt and the maleate, i.e., (Z)-2-butenedioate, salt.
Compounds of formula (V) and their salts can be prepared by processes known per se, including processes described in patent literature cited herein. However, the present invention is not restricted by the process used to prepare the therapeutic agent. Preferred compounds of formula (V) are those disclosed generically or
specifically in U.S. Patent No. 5,273,975 to Moon et al. Especially preferred compounds are those of formula (VI)
(Formula Removed)
wherein X is O or S, and pharmaceutically acceptable salts thereof.
Tablet cores useful according to the invention can be prepared by any suitable process known in the art. A core according to the invention comprises a matrix wherein are distributed solid particles of a water-soluble dye. Any suitable excipient or excipients can form the matrix. For peroral tablets the matrix typically comprises a diluent or carrier, for example lactose and/or starch, and can further comprise additional excipients such as binders, disintegrants, wetting agents, etc. For intraoral tablets the matrix typically comprises a water-soluble sugar, for example mannitol and/or maltose. If a drug is present in the core, the drug, too, is distributed in the matrix.
The ultimate appearance of the tablet depends in part upon the selection of water-soluble dye and the number and size of the solid particles of the dye. For example, relatively large particles will tend to produce a speckled pattern having larger blocks of color than will be produced by smaller particles; and a relatively large number of particles will tend to produce a speckled pattern where the color covers a greater portion of the tablet surface than will be produced by fewer particles. A more water-soluble dye will tend to produce larger and/or less discrete blocks of color than will be produced by a less water-soluble dye.
Optionally solid particles of more than one water-soluble dye can be present in the core, contributing a bicolored or multicolored speckled appearance to the tablet.
The core is coated with a coating composition comprising gellan gum, as more fully described below. The coating is typically present in an amount representing a weight gain of about 0.1% to about 5%, but greater or lesser amounts can be used if desired. Preferably the gellan gum constitutes about 25% to 100%, more preferably about 50% to 100%, by weight of the coating.
Preferably the coating is an excipient coating. An "excipient coating" herein is a coating consisting, at least at the time 'of application of the coating to the core, only
!•
of excipient materials, i.e., having substantially no drug present therein. It will be understood that during manufacture and storage some migration of a drug substance can potentially occur from the core to the coating of a tablet of the invention, but this is generally minimal. Thus a drug substance, if present in the tablet, is largely confined to the core where it is not commingled with gellan gum.
Any gellan gum can be used in the coating composition, but it is preferred to use a deacylated gellan gum such as that sold under the trademark Kelcogel™. Optionally one or more additional gums and/or biopolymers, for example alginates, can be present in the coating composition.
The coating composition comprises a sprayable vehicle, preferably water, having dissolved or dispersed therein a gellan gum and optionally one or more additional excipients. Preferably the coating composition has a total solids concentration of about 1% to about 10% by weight, and a gellan gum concentration of about 1% to about 5% by weight.
Additional excipients present in the coating composition can include one or more buffering agents, typically at a concentration of about 0.03% to about 3% by weight; one or more plasticizers, typically at a concentration of about 0.03% to about 3% by weight; and/or one or more dispersing and/or emulsifying agents, typically at a concentration of about 0.03% to about 3% by weight. An example of a suitable buffering agent is sodium citrate. An example of a suitable plasticizer is propylene glycol. An example of a suitable dispersing or emulsifying agent is lecithin. Flavoring agents can also be included in the coating composition if desired.
The coating composition can be prepared by any suitable process involving dissolving the gellan gum and other, optional, excipients in the vehicle, preferably water. Order of addition is not critical. The water is preferably heated, for example to a temperature of about 55°C to about 85°C. Gellan gum and other excipients, if present, are added with stirring until all ingredients are homogeneously dispersed. The resulting coating liquid is preferably maintained at an elevated temperature during the stirring and subsequent spraying procedure.
Tablet cores to be coated are placed in a suitable coating apparatus, for
example a coating pan, and are preferably preheated to a bed temperature of about 50°C to about 70°C. The coating liquid is sprayed on to the tablets under conditions that will be readily optimized by one of skill in the art.. Spraying is continued until an amount of coating solution equivalent to a weight gain of about 0.1% to about 5% has been applied, The resulting coated tablets are preferably cooled to ambient temperature, or about 20°C to about 35°C, prior to discharge from the coating pan.
Coating and cooling conditions can also affect the precise color pattern of the finished tablet. For example, if coating is done at lower temperatures and/or if cooling occurs slowly, so that the solid dye particles in the core are exposed to water for a longer period of time, a speckled pattern with larger blocks of color will typically result.
An illustrative sublingual tablet of the invention containing as active agent a
salt, e.g., the maleate salt, of sumanirole or (R)-5,6-dihydro-5-(methylamino)-4H-
imidazo[4,5-ij]-quinohne-2(lH)-thione has a core having the following composition:
active agent 0.1-3% free base equivalent
mannitol 50-90%
powdered sorbitol 10-40%
hydroxypropylcellulose 0-10%
xanthan gum 0-5%
flavoring agent 0-0.5%
water-soluble dye 0-0.5%
colloidal silicon dioxide 0-1 %
magnesium stearate 0.5—5%
all percentages being by weight.
Another illustrative sublingual tablet of the invention containing as active agent
a salt, e.g., the maleate salt, of sumanirole or (R)-5,6-dihydro-5-(methylamino)-4H-
imidazo[4,5-ij]-quinoline-2(lH)-thione has a core having the following composition:
active agent 0.1-3% free base equivalent
lactose monohydrate 50-85%
pregelatinized starch 10-45%
xanthan gum 0-5%
flavoring agent 0-0.5%
water-soluble dye 0—0.5%
colloidal silicon dioxide 0-1%
magnesium stearate 0.5-5%
all percentages being by weight.
Yet another illustrative sublingual tablet of the invention containing as active agent a salt, e.g., the maleate salt, of sumanirole or (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(lH)-thione has a core having the following composition:
active agent 0,1-3 % free base equivalent
micro crystalline cellulose 30-70%
pregelatinized starch 25-65%
croscarmellose sodium 0-10%
xanthan gum 0-5%
flavoring agent 0-0.5%
water-soluble dye 0-0.5%
colloidal silicon dioxide 0-1%
magnesium stearate 0.5-5%
all percentages being by weight.
EXAMPLES
The following examples illustrate aspects of the present invention but should not be construed as limitations. In these examples "compound Z" refers to (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoUne-2(lH)-thione, maleate salt. All percentages are by weight unless otherwise indicated.
Example 1
A sublingual tablet formulation was prepared having the following
composition:
compound Z 1.11%
Avicel™PH-101 (microcrystalline cellulose) 46.71%
Starch 1500 of Colorcon (pregelatinized starch) 44.00%
croscarmellose sodium NF 5.00%
colloidal silicon dioxide NF 0.50%
cinnamon flavor 0.14%
mint flavor 0.04%
dye (cherry shade #1632, Crompton & Knowles) 0.50%
magnesium stearate 2.00%
Pregelatinized starch and dye were blended in a high-shear mixer for 2 minutes or until homogeneously mixed. The following ingredients were then individually layered over the resulting mixture in the high-shear mixer: compound Z; micro crystalline cellulose; colloidal silicon dioxide; croscarmellose sodium. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the dye was not adequately dispersed throughout the resulting mixture, mixing continued in 1 minute increments until good dispersion of dye was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was added to the high-shear mixer and mixed for 1 minute to form a lubricated tablet stock.
The lubricated tablet stock was discharged from the high-shear mixer and
stored in desiccated hermetically sealed containers until ready for tabletiug. Tablets
were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain
tooling with slight curvature to the following specifications:
tablet weight 18 0 mg
hardness 3-4 SCU
friability Example 2
Sublingual tablets prepared as in Example 1 were coated with a gellan gum coating according to the following procedure.
A coating liquid having the following composition was prepared:
gellan gum (Kelcogel™) 2.00%
sodium citrate 0.13%
propylene glycol 0.40%
lecithin 0.20%
deionized water 97.27%
Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating
liquid having a solids content of 2.73% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure.
Tablets of Example 1, in an arribunt of 700 g, were placed in a 12 inch
(approximately 300 mm) coating pan and preheated to a bed temperature of 60°C.
The coating liquid was sprayed on to the tablets under the following conditions:
outlet air temperature 50-60°C
pan speed 16rpm
air flow 30-35 cfrn (0.84-0.98 mVminute)
atomizing air pressure 10psi(69kPa)
peristaltic pump setting 15-20 g/minute
Spraying was continued until an amount of coating solution equivalent to a weight gain of 1.2% had been applied: The resulting coated tablets were cooled to 30°C prior to discharge from the coating pan.
The tablets had an attractive high gloss appearance with cherry red speckles.
Example 3
A sublingual tablet formulation was prepared having the following composition:
compound Z 1.05%
mannitol, granular 70.00%
sorbitol 16.57%
hydroxypropylcellulose., type LH-11 7.00%
xanthan gum 2.50%
colloidal silicon dioxide NF 0.50%
cinnamon flavor 0.14%
mint flavor 0.04%
dye (cherry shade #1632, Crompton & Knowles) 0.20%
magnesium stearate 2.00%
Mannitol and dye were blended in a high-shear mixer for 2 minutes or until homogeneously mixed. The following ingredients were then individually layered over the resulting mixture in the high-shear mixer: compound Z; sorbitol; hydroxypropylcellulose; xanthan gum; colloidal silicon dioxide. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the dye was not adequately
dispersed throughout the resulting mixture, mixing continued in 1 minute increments until good dispersion of dye was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was added to the high-shear mixer and mixed for 1 minute to form a lubricated tablet stock.
The lubricated tablet stock was discharged from the high-shear mixer and stored in desiccated hermetically sealed containers until ready for tableting. Tablets were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain tooling with slight curvature to the following specifications:
tablet weight . 190 mg
hardness 3-4 SCU
friability Example 4
Sublingual tablets prepared as in Example 3 were coated with a gellan gum coating according to the following procedure.
A coating liquid having the following composition was prepared:
gellan gum (Kelcogel™) 2.00%
sodium citrate 0.13%
propylene glycol 0.40%
lecithin (Lipoid™ LS-100) 0.20%
flavor 0.30%
deionized water 96.97%
Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating liquid having a solids content of 3.03% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure.
Tablets of Example 1, in an amount of 700 g, were placed in a 12 inch
(approximately 300 mm) coating pan and preheated to a bed temperature of 60°C.
The coating liquid was sprayed on to the tablets under the following conditions:
outlet air temperature 50-60°C
pan speed 16rpm
air flow 30-35 cfrn (0.84-0.98 mVminute)
atomizing air pressure 10 psi (69 kPa)
peristaltic pump setting 15-20 g/minute
Spraying was continued until an amount of coating solution equivalent to a weight gain of 1.36% had been applied. The resulting coated tablets were cooled to 30°C prior to discharge from the coating pan.
The tablets had an attractive high gloss appearance with cherry red speckles.
Example 5
A sublingual tablet formulation was prepared having the following composition:
compound Z 0.43%
Avicel™ PH-101 (microcrystalHne cellulose) 47.39%
Starch 1500 of Colorcon (pregelatinized starch) 44.00%
croscarmellose sodium NF 5.00%
colloidal silicon dioxide NF 0.50%
cinnamon flavor 0.14%
mint flavor 0.04%
color (cherry shade #1632, Crompton & Knowles) 0.50%
magnesium stearate 2.00%
Pregelatinized starch and color were blended in a high-shear mixer for 2 minutes or until homogeneously mixed. The following ingredients were then individually layered over the resulting mixture in the high-shear mixer: compound Z; micro crystalline cellulose; colloidal silicon dioxide; croscarmellose sodium. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the color was not adequately dispersed throughout the resulting mixture, mixing continued in 1 minute increments until good dispersion of color was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was hand screened through a #20 mesh pharmaceutical screen, then added to the high-shear mixer and mixed for 1 minute to form a lubricated tablet stock.
The lubricated tablet stock was discharged from the high-shear mixer and stored in desiccated hermetically sealed containers until ready for tableting. Tablets were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain
tooling with slight curvature to the following specifications:
tablet weight 180 mg
hardness 3.5-4 SCU
friability Example 6
Sublingual tablets prepared as in Example 5 were coated with-a gellan gum coating according to the following procedure.
A coating liquid having the following composition was prepared:
gellan gum (Kelcogel™) 2.00%
s o dium citrate 0.13%
propylene glycol 0.40%
lecithin (Lipoid™ LS-100) 0.20%
hot cinnamon flavor 0.30%
deionized water 96.97%
Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating liquid having a solids content of 3.03% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure.
Tablets of Example 5, in an amount of 7000 g, were placed in a 24 inch
(approximately 600 mm) coating pan and preheated to a bed temperature of 60°C.
The coating liquid was sprayed on to the tablets under the following conditions:
outlet air temperature 48—55°C
pan speed 10—14 rpm, preferably 14 rpm
air flow 300-400 cfrn (8.5-11.3 mVminute)
atomizing air pressure 20-35 psi (138-242 kPa),
preferably about 20 psi
peristaltic pump setting 15-40 g/minute/gun (2 gun spray system),
preferably 30-40 g/minute/gun
tablet bed temp 37-50°C, preferably about 40°C
Spraying was continued until an amount of coating solution equivalent to a weight gain of 2.04% had been applied. The resulting coated tablets were cooled to 30°C prior to discharge from the coating pan.
The tablets had an attractive high gloss appearance with cherry red speckles.

WE CLAIM:
1. A pharmaceutical tablet comprising a core and a coating adherent
thereto, wherein (a) the core comprises solid particles of a water-soluble
dye distributed in a matrix, and (b) the coating comprises gellan gum;
and wherein the core comprises a drug in a therapeutically and/or
prophylactically effective amount.
2. The tablet as claimed in claim 1 having a speckled surface
appearance.
3. The tablet as claimed in claim 1 wherein the drug is selected from
the group consisting of ACE inhibitors; a-adrenergic agonists; ß-
adrenergic agonists; a-adrenergic blockers; ß-adrenergic blockers;
alcohol deterrents; aldose reductase inhibitors; aldosterone antagonists;
amino acids; anabolics; analgesics (both narcotic and non-narcotic);
anesthetics; anorexics; antacids; anthelmintics; antiacne agents;
antiallergics; antiandrogens; antianginal agents; antianxiety agents;
antiarrythmics; antiasthmatics; antibacterial agents and antibiotics;
antialopecia and antibaldness agents; antiamebics; antibodies;
anticholinergic drugs; anticoagulants and blood thinners; anticolitis
drugs; anticonvulsants; anticystitis drugs; antidepressants; antidiabetic
agents; antidiarrheals; antidiuretics; antidotes; antiemetics;
antiestrogens; antiflatulents; antifungal agents; antigens; antiglaucoma
agents; antihistaminics; antihyperactives; antihyperlipoproteinemics;
antihypertensives; antihyperthyroid agents; antihypotensives;
antihypothyroid agents; anti-infectives; anti-inflammatories (both
steroidal and nonsteroidal) antimalarial agents; antimigraine agents;
antineoplastics; antiobesity agents; antiparkinsonian agents and
antidyskinetics; antipneumonia agents; antiprotozoal agents;
antipruritics; antipsoriatics; antipsychotics; antipyretics;
antirheumatics; antisecretory agents; anti-shock medications;
antispasmodics; antithrombotics; antitumor agents; antitussives; antiulceratives; antiviral agents; anxiolytics; bactericidins; bone densifiers; bronchodilators; calcium channel blockers; carbonic anhydrase inhibitors; cardiotonics and heart stimulants; chemotherapeutics; choleretics; cholinergics; chronic fatigue syndrome medications; CNS stimulants; coagulants; contraceptives; cystic fibrosis medications; decongestants; diuretics; dopamine receptor agonists; dopamine receptor antagonists; enzymes; estrogens; expectorants; gastric hyperactivity medications; glucocorticoids; hemostatics; HMG CoA reductase inhibitors; hormones; hypnotics; immunomodulators; immunosuppressants; laxatives; medicaments for oral and periodontal diseases; miotics; monoamine oxidase inhibitors; mucolytics; multiple sclerosis medications; muscle relaxants; mydriatics; narcotic antagonists; NMDA receptor antagonists; oligonucleotides; ophthalmic drugs; oxytocics; peptides, polypeptides and proteins; polysaccharides; progestogens; prostaglandins; protease inhibitors; respiratory stimulants; sedatives; serotonin uptake inhibitors; sex hormones including androgens; smoking cessation drugs; smooth muscle relaxants; smooth muscle stimulants; thrombolytics; tranquilizers; urinary acidifiers; urinary incontinence medications; vasodilators; vasoprotectants; and combinations thereof.
4. The tablet as claimed in claim 1 wherein the drug is a smoking
cessation drug.
5. The tablet as claimed in claim 4 wherein the smoking cessation
drug is selected from bupropion, ibogaine, nicotine and metabolites
thereof.
6. The tablet as claimed in claim 1 wherein the drug is an
antibacterial drug.
7. The tablet as claimed in claim 6 wherein the antibacterial drug is
x
an oxazolidinone.
8. The tablet as claimed in claim 7 wherein the oxazolidinone is
selected from eperezolid, linezolid, N-[(5S) -3-[3-fluoro-4-[4-(2-
fluoroethyl)-3-oxo-1 -piperazinyl]phenyl-2-oxo-5-
oxazolidinyl]methyl]acetamide, (S)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide, and (S)-N-[[3-[5)-(4-pyridyl)pyrid-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride.
9. The tablet as claimed in claim 1 wherein the drug is an
antimigraine agent.
10. The tablet as claimed in claim 9 wherein the antimigraine agent is
a 5-HT receptor agonist.
11. The tablet as claimed in claim 10 wherein the 5-HT receptor
agonist is selected from the group consisting of almotriptan, eletriptan,
frovatriptan, naratriptan, rizatriptan, sumatriptan or zolmitriptan.
12. The tablet as claimed in claim 1 wherein the drug is an
antiglaucoma or intraocular pressure lowering agent.
13. The tablet as claimed in claim 12 wherein the antiglaucoma or
intraocular pressure lowering agent is selected from the group consisting
of adrenolone, apraclonidine, brimonidine, dipivefrin, acebutolol,
adaprolol, alprenolol, atenolol, betaxolol, bufetolol, bufuralol, bunitrolol,
bunolol, bupranolol, carteolol, carvedilol, cetamolol, dexpropanolol,
labetalol, levobunolol, metipranolol, metoprolol, nadolol, nifenalol,
oxyprenolol, penbutolol, pindolol, practolol, pronethalol, propranolol,
sotalol, timolol, tolamolol, toliprolol, vaninolol, acetazolamide,
dorzolamide, bimatoprost, latanoprost, travoprost, unoprostone isopropyl and combinations thereof.
14. The tablet as claimed in claim 1 wherein the drug is an analgesic,
antipyretic or anti-inflammatory agent.
15. The tablet as claimed in claim 14 wherein the analgesic,
antipyretic or anti-inflammatory agent is selected from the group
consisting of aceclofenac, acemetacin, e-acetamidocaproic acid,
acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid, S-
adenosylmethionine, alclofenac, alclometasone, alfentanil, algestone,
allylprodine, alminoprofen, aloxiprin, alphaprodine, aluminum
bis(acetylsalicylate), amcinonide amfenac, aminochlorthenoxazin, 3-
amino-4-hydroxybutyric acid, 2-amino-4-picoline, aminopropylon,
aminopyrine, amixetrine, ammonium salicylate, ampiroxicam,
amtolmetin guacil, anileridine, antipyrine, antrafenine, apazone,
beclomethasone, bendazac, benorylate, benoxaprofen, benzpiperylon,
benzydamine, benzylmorphine, bermoprofen, betamethasone,
bezitramide, a-bisabolol, bromfenac, p-bromoacetanilide, 5-
bromosalicylic acid acetate, bromosaligenin, bucetin, bucloxic acid,
bucolome, budesonide, bufexamac, bumadizon, buprenorphine,
butacetin, butibufen, butophanol, carbamazepine, carbiphene,
carprofen, carsalam, celecoxib, chlorobutanol, chloroprednisone,
chlorthenoxazin, choline salicylate, cinchophen, cinmetacin, ciramadol,
clidanac, clobetasol, clocortolone, clometacin, clonitazene, clonixin,
clopirac, cloprednol, clove, codeine, codeine methyl bromide, codeine
phosphate, codeine sulfate, cortisone, cortivazol, cropropamide,
crotethamide, deflazacort, desomorphine, desonide, desoximetasone,
dexamethasone, dexoxadrol, dextromoramide, dezocine, diampromide,
diclofenac, difenamizole, difenpiramide, diflorasone, diflucortolone,
diflunisal, difluprednate, dihydrocodeine, dihydrocodeinone enol acetate,
dihydrornorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol,
dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone,
diprocetyl, dipyrone, ditazol, droxicam, emorfazone, enfenamic acid,
enoxolone, epirizole, eptazocine, etersalate, ethenzamide, ethoheptazine,
ethoxazene, ethylmethylthiambutene, ethylmorphine, etodolac,
etofenarnate, etonitazene, etoricoxib, eugenol, felbinac, fenbufen,
fenclozic acid, fendosal, fenoprofen, fentanyl, fentiazac, fepradinol,
feprazone, floctafenine, fluazacort, flucloronide, flufenamic acid,
flumethasone, flunisolide, flunixin, flunoxaprofen, fluocinolone
acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluoresone,
fluorometholone, fluperolone, flupirtine, fluprednidene, fluprednisolone,
fluproquazone, flurandrenolide, flurbiprofen, formocortal, fosfosal,
gentisic acid, glafenine, glucametacin, glycol salicylate, guaiazulene,
halcinonide, halometasone, haloprednone, hydrocodone,
hydrocortamate, hydrocortisone, hydromorphone, hydroxypethidine,
ibufenac, ibuprofen, ibuproxam, imidazole salicylate. indomethacin,
indoprofen, isofezolac, isoladol, isomethadone, isonixin, isoxepac,
isoxicam, ketobemidone, ketoprofen, ketorolac, p-lactophenetide,
lefetamine, levorphanol, lofentanil, lonazolac, lornoxicam, loxoprofen,
lysine acetylsalicylate, mazipredone, meclofenamic acid, medrysone,
mefenamic acid, meperidine, meprednisone, meptazinol, mesalamine,
metazocine, methadone, methotrimeprazine, methylprednisolone,
metiazinic acid, metofoline, metopon, mofebutazone, mofezolac,
morazone, morphine, morphine hydrochloride, morphine sulfate,
morpholine salicylate, myrophine, nabumetone, nalbuphine, 1-naphthyl
salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone,
niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol,
normethadone, normorphine, norpipanone, olsalazine, opium, oxaceprol,
oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone,
papaveretum, paramethasone, paranyline, parecoxib, parsalmide,
pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine,
phenazopyridine hydrochloride, phenocoll, phenoperidine,
phenopyrazone, phenyl acetylsalicylate, phenylbutazone, phenyl
salicylate, phenyrarmidol, piketoprofen, piminodine, pipebuzone, piperylone, piprofen, pirazolac, piritramide, piroxicam, pranoprofen, prednicarbate, prednisolone, prednisone, prednival, prednylidene, progiumetacin, proheptazine, promedol, propacetamol, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, rofecoxib, salacetamide, salicin, salicylamide, salicylamide o-acetic acid, salicylic acid, salicylsulfuric acid, salsalate, salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, tropesin, valdecoxib, viminol, xenbucin, ximoprofen, zaltoprofen and zomepirac.
16. The tablet as claimed in claim 14 wherein the analgesic,
antipyretic or anti-inflammatory agent is a selective COX-2 inhibitory
drug.
17. The tablet as claimed in claim 16 wherein the selective COX-2
inhibitory drug is a compound having the formula

(Formula Removed)

where R15 is a methyl, amino or imide group, R16 is hydrogen or a Ci-4 alkyl or alkoxy group, X is N or CR17 where R17 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six membered ring that is unsubstituted or
substituted at one or more positions with oxo, halo, methyl or halomethyl groups.
18. The tablet as claimed in claim 16 wherein the selective COX-2
inhibitor is selected from the group consisting of celecoxib, deracoxib,
valdecoxib, parecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-
(methylsulfonyl)phenyl]-2-cyclopenten-1- one, (S)-6,8-dichloro-2-
(trifluoromethyl)-2H-l-benzopyran-3-carboxylic acid, 2-(3,4-
difluorophenyl)-4-(3-hydroxy-3-methyl-1-butyoxy)-5-[4-
(methylsulfonyl)phenyl]-3-(2H)-pyridazinone and salts thereof.
19. The tablet as claimed in claim 1 wherein the drug is an agent
selected from the group consisting of PDE5 inhibitors, cyclic AMP
activators, a-adrenergic antagonists and dopaminergic agonists.
20. The tablet as claimed in claim 19 wherein the agent is a compound
of formula
(Formula Removed)
or a pharmaceutically acceptable salt thereof; wherein
R1, R2 and R3 are the same or different and are H, C1-6 alkyl (optionally
phenyl substituted), C3-5 alkenyl or alkyayl or C3-10 cycloalkyl, or where
R3 is as above and R1 and R2 are cyclized with the attached N atom to
form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or
imidazolyl groups;
X is H, F, Cl, Br, I, OH, C1-6 alkyl or alkoxy, CN, carboxamide, carboxyl or
(C1-6 alkyl) carbonyl;

A is CH, CH2, CHF, CHCl, CHBr, CHI, CHCH3, C=O, C=S, CSCH3, C=NH,
CNH2, CNHCH3, CNHCOOCH3, CNHCN, SO2 or N;
B is CH, CH2, CHF, CHCl, CHBr, CHI, C=O, N, NH or NCH3 and n is 0 or
1; and
D is CH, CH2, CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH3.
21. The tablet as claimed in 19 wherein the agent is a compound of formula

(Formula Removed)

wherein X is O or S, or a pharmaceutically acceptable salt thereof.
22. The tablet as claimed in claim 1 wherein the coating is present in
an amount representing a weight gain of 0.1% to 5%.
23. The tablet as claimed in claim 1 wherein the gellan gum
constitutes 25% to 100% by weight of the coating.
24. The tablet as claimed in claim 1 wherein the gellan gum
constitutes 50% to 100% by weight of the coating.
25. The tablet as claimed in claim 1 wherein the coating further
comprises at least one additional excipient selected from the group
consisting of buffering agents, plasticizers and dispersing and
emulsifying agents.

Documents:

2122-delnp-2004-abstract.pdf

2122-delnp-2004-claims.pdf

2122-delnp-2004-correspondence-others.pdf

2122-delnp-2004-correspondence-po.pdf

2122-delnp-2004-description (complete).pdf

2122-delnp-2004-form-2.pdf

2122-delnp-2004-form-3.pdf

2122-delnp-2004-gpa.pdf

2122-delnp-2004-pct-101.pdf

2122-delnp-2004-pct-210.pdf

2122-delnp-2004-pct-304.pdf

2122-delnp-2004-pct-308.pdf

2122-delnp-2004-pct-401.pdf

2122-delnp-2004-pct-402.pdf

2122-delnp-2004-pct-409.pdf

2122-delnp-2004-pct-416.pdf

2122-delnp-2004-petition-137.pdf

2122-delnp-2004-petition-138.pdf

« Previous Patent

Next Patent »

Patent Number

219622

Indian Patent Application Number

2122/DELNP/2004

PG Journal Number

26/2008

Publication Date

27-Jun-2008

Grant Date

12-May-2008

Date of Filing

22-Jul-2004

Name of Patentee

PHARMACIA CORPORATION

Applicant Address

Inventors:

#	Inventor's Name	Inventor's Address
1	ALICE C. MARTINO
2	STEVEN A. PIERMAN
3	ROBERT M. NOACK

PCT International Classification Number

A61K 9/34

PCT International Application Number

PCT/US03/03837

PCT International Filing date

2003-02-06

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	60/355,705	2002-02-07	U.S.A.